New Hyde Park, NEW%20YORK2 Active Studies

Pulmonary Hypertension Clinical Trials in New Hyde Park, NEW%20YORK

Find 2 actively recruiting pulmonary hypertension clinical trials in New Hyde Park, NEW%20YORK. Connect with local research sites and explore new treatment options.

2
Active Trials
2
Sponsors
315
Enrolling

Recruiting Pulmonary Hypertension Studies in New Hyde Park

About Pulmonary Hypertension Clinical Trials in New Hyde Park

Pulmonary hypertension is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It can lead to heart failure if untreated. Treatment includes vasodilators, endothelin receptor antagonists, and PDE-5 inhibitors.

There are currently 2 pulmonary hypertension clinical trials recruiting participants in New Hyde Park, NEW%20YORK. These studies are seeking a combined 315 participants. Research is being sponsored by Pfizer, Vanda Pharmaceuticals. Clinical trial participation is free and participants receive study-related medical care at no cost.

Pulmonary Hypertension Clinical Trials in New Hyde Park — FAQ

Are there pulmonary hypertension clinical trials in New Hyde Park?

Yes, there are 2 pulmonary hypertension clinical trials currently recruiting in New Hyde Park, NEW%20YORK. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New Hyde Park?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New Hyde Park research site will contact you about next steps.

Are clinical trials in New Hyde Park free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New Hyde Park studies also compensate for your time and travel.

What pulmonary hypertension treatments are being tested?

The 2 active trials in New Hyde Park are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary hypertension.

Data updated March 2, 2026 from ClinicalTrials.gov